Skip to main content
SpringerLink
Log in

Therapieresistenz unipolarer depressiver Erkrankungen: Häufigkeit, Prädiktoren, Risikofaktoren

  • Chapter
Akute und therapieresistente Depressionen

Zusammenfassung

Therapieresistenz im Rahmen der medikamentösen Behandlung von unipolaren Depressionen ist häufig. Etwa 20–30% der behandelten Patienten sprechen nicht oder nicht ausreichend an. Etwa 10–20% der Patienten leiden an chronischer depressiver Symptomatik. Die Vorhersagemöglichkeiten hinsichtlich der Therapieresistenz sind begrenzt. Anamnestische und psychopathologische Charakteristika haben dabei bisher größere Bedeutung als biologische Parameter, die eher von theoretischer Bedeutung sind.

Ein großes Problem der Depressionsbehandlung mit Antidepressiva liegt darin, dass nicht alle behandelten Patienten im Laufe der medikamentösen Therapie eine ausreichende Besserung erfahren. Das gilt besonders, wenn man auf Remission und nicht nur auf Response abzielt (Möller 1990; Hirschfeld et al. 2002).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 119.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 159.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Aberg Wistedt A, Jostell KG, Ross SB, Westerlund D (1981) Effects of zimelidine and desipramine on serotonin and noradrenaline uptake mechanisms in relation to plasma concentrations and to therapeutic effects during treatment of depression. Psychopharmacology Berl 74: 297–305

    Article  PubMed  Google Scholar 

  • Alda M (2001) Genetic factors and treatment of mood disorders. Bipolar Disord 3: 318–324

    Article  PubMed  Google Scholar 

  • Ansseau M, Kupfer DJ, Reynolds CF3, Coble PA (1985) »Paradoxical« shortening of REM latency on first recording night in major depressive disorder: clinical and polysomnographic correlates. Biol Psychiatry 20: 135–145

    Article  PubMed  Google Scholar 

  • Arias B, Arranz MJ, Gasto C, Catalan R, Pintor L, Gutierrez B, Kerwin RW, Fananas L (2002) Analysis of structural polymorphisms and C-1018G promoter variant of the 5-HT(1A) receptor gene as putative risk factors in major depression. Mol Psychiatry 7: 930–932

    Article  PubMed  Google Scholar 

  • Arranz MJ, Collier D, Kerwin RW (2001) Pharmacogenetics for the individualization of psychiatric treatment. Am J Pharmacogenomics 1: 3–10

    PubMed  Google Scholar 

  • Bertilsson L, Dahl ML, Tybring G (1997) Pharmacogenetics of antidepressants: clinical aspects. Acta Psychiatr Scand Suppl 391: 14–21

    PubMed  Google Scholar 

  • Burrows GD, Norman TR, Judd FK (1994) Definition and differential diagnosis of treatment-resistant depression. Int Clin Psychopharmacol 9[Suppl 2]: 5–10

    Google Scholar 

  • Coble PA, Kupfer DJ, Spiker DG, Neil JF, McPartland RJ (1979) EEG sleep in primary depression. A longitudinal placebo study. J Affect Disord 1: 131–138

    Article  PubMed  Google Scholar 

  • Del Zompo M, Ardau R, Palmas MA, Bocchetta A, Reina A, Piccardi MP (1999) Lithium response: association study with two candidate genes. Mol Psychiatry 4: 66–67

    Article  Google Scholar 

  • Dietzfelbinger T, Möller HJ, Steinmeyer EM, Fimmers R (1990) Elektrokrampftherapie als Ultima ratio bei Antidepressiva-Nonrespondern. In: Möller HJ (Hrsg) Therapieresistenz unter Antidepressiva-Behandlung. Tropon-Symposium V. Springer, Berlin Heidelberg New York Tokio, S. 167–185

    Google Scholar 

  • Dinan TG (1993) A rational approach to the non-responding depressed patient. Int Clin Psychopharmacol 8: 221–223

    PubMed  Google Scholar 

  • Fava M, Davidson KG (1996) Definition and epidemiology of treatment-resistant depression. Psychiatr Clin North Am 19: 179–200

    Article  PubMed  Google Scholar 

  • Fava M, Rosenbaum JF, McGrath PJ, Stewart JW, Amsterdam JD, Quitkin FM (1994) Lithium and tricyclic augmentation of fluoxetine treatment for resistant major depression: a double-blind, controlled study. Am J Psychiatry 151: 1372–1374

    PubMed  Google Scholar 

  • Fawcett J, Maas JW, Dekirmenjian H (1972) Depression and MHPG excretion: Response to dextroamphetamine and tricyclic antidepressants. Arch Gen Psychiatry 26: 246–251

    PubMed  Google Scholar 

  • Healy D, Carney PA, Leonard BE (1984) Biochemical correlates of antidepressant response. Results of a trazodone versus amitriptyline trial. Psychopathology 17[Suppl 2]: 82–87

    PubMed  Google Scholar 

  • Hegerl U, Gallinat J, Juckel G (2001) Event-related potentials: Do they reflect central serotonergic neurotransmission and do they predict clinical response to serotonin agonists? J Affect Disord 62: 93–100

    Article  PubMed  Google Scholar 

  • Hirschfeld RMA, Montgomery SA, Aguglia E et al. (2002) Partial response and nonresponse to antidepressant therapy: current approaches and treatment options. J Clin Psychiatry 63: 826–837

    PubMed  Google Scholar 

  • Höchli D, Riemann D, Zulley J, Berger M (1986) Initial REM sleep suppression by clomipramine: a prognostic tool for treatment response in patients with a major depressive disorder. Biol Psychiatry 21: 1217–1220

    PubMed  Google Scholar 

  • Hollister LE, Davis KL, Berger PA (1980) Subtypes of depression based on excretion of MHPG and response to nortriptyline. Arch Gen Psychiatry 37: 1107–1110

    PubMed  Google Scholar 

  • Hong CJ, Wang YC, Tsai SJ (2002) Association study of angiotensin I-converting enzyme polymorphism and symptomatology and antidepressant response in major depressive disorders. J Neural Transm 109: 1209–1214

    Article  PubMed  Google Scholar 

  • Judd LL, Akiskal HS, Maser JD et al. (1998a) A prospective 12-year study of subsyndromal and syndromal depressive symptoms in unipolar major depressive disorders. Arch Gen Psychiatry 55: 694–700

    Article  PubMed  Google Scholar 

  • Judd LL, Akiskal HS, Maser JD et al. (1998b) Major depressive disorder: a prospective study of residual subthreshold depressive symptoms as predictor of rapid relapse. J Affect Disord 50: 97–108

    PubMed  Google Scholar 

  • Judd LL, Paulus MJ, Schettler PJ et al. (2000) Does incomplete recovery from first lifetime major depressive episode herald a chronic course of illness? Am J Psychiatry 157: 1501–1504

    Article  PubMed  Google Scholar 

  • Keller MB (2002) Rationale and options for the long-term treatment of depression. Hum Psychopharmacol 17[Suppl 1]: S43–S46

    Article  PubMed  Google Scholar 

  • Keller MB (2003) Past, present, and future directions for defining optimal treatment outcome in depression: remission and beyond. JAMA 289: 3152–3160

    Article  PubMed  Google Scholar 

  • Keller MB et al. (1984) Long-term outcome of episodes of major depression. J Am Med Assoc 252: 788–792

    Article  Google Scholar 

  • Keller MB, Gelenberg AJ, Hirschfeld RM et al. (1998) The treatment of chronic depression, part 2: a double-blind, randomized trial of sertraline and imipramine. J Clin Psychiatry 59: 598–607

    Google Scholar 

  • Keller MB, Hirschfeld RM, Demyttenaere K, Baldwin DS (2002) Optimizing outcomes in depression: focus on antidepressant compliance. Int Clin Psychopharmacol 17: 265–271

    PubMed  Google Scholar 

  • Kelwala S, Jones D, Sitaram N (1983) Monoamine metabolites as predictors of antidepressant response: a critique. Prog Neuropsychopharmacol Biol Psychiatry 7: 229–240

    PubMed  Google Scholar 

  • Kim DK, Lim SW, Lee S, Sohn SE, Kim S, Hahn CG, Carroll BJ (2000) Serotonin transporter gene polymorphism and antidepressant response. Neuroreport 11: 215–219

    Google Scholar 

  • Klein DN, Schatzberg AF, McCullough JP et al. (1999) Age of onset in chronic major depression: relation to demographic and clinical variables, family history, and treatment response. J Affect Disord 55: 149–157

    Article  PubMed  Google Scholar 

  • Koran LM, Gelenberg AJ, Kornstein SG et al. (2001) Sertraline versus imipramine to prevent relapse in chronic depression. J Affect Disord 65: 27–36

    Article  PubMed  Google Scholar 

  • Leon AC, Solomon DA, Mueller TI et al. (2003) A 20-year longitudinal observational study of somatic antidepressant treatment effectiveness. Am J Psychiatry 160: 727–733

    Article  PubMed  Google Scholar 

  • Maas JW, Fawcett JA, Dekirmenjian H (1972) Catecholamine metabolism, depressive illness, and drug response. Arch Gen Psychiatry 26: 252–262

    PubMed  Google Scholar 

  • Maas JW, Kocsis JH, Bowden CL et al. (1982) Pretreatment neurotransmitter metabolites and response to imipramine or amitriptyline treatment. Psychol Med 12: 37–43

    PubMed  Google Scholar 

  • Maas JW, Koslow SH, Katz MM et al. (1984) Pretreatment neurotransmitter metabolite levels and response to tricyclic antidepressant drugs. Am J Psychiatry 141: 1159–1171

    PubMed  Google Scholar 

  • Mancama D, Kerwin RW (2003) Role of pharmacogenomics in individualising treatment with SSRIs. CNS Drugs 17: 143–151

    PubMed  Google Scholar 

  • Montgomery SA, Dufour H, Brion S et al. (1988) The prophylactic efficacy of fluoxetine in unipolar depression. Br J Psychiatry [Suppl 3]: 69–76

    Google Scholar 

  • Möller HJ (Hrsg) (1990) Therapieresistenz unter Antidepressiva-Behandlung. Springer, Berlin Heidelberg New York Tokio

    Google Scholar 

  • Möller HJ, Fischer G, von Zerssen D (1987) Prediction of therapeutic response in acute treatment with antidepressants. Results of an empirical study involving 159 endogenous depressive inpatients. Eur Arch Psychiatry Neurol Sci 236: 349–357

    Article  PubMed  Google Scholar 

  • Möller HJ, Kissling W, Baumann P et al. (1988) Nonresponse to antidepressants: risk factors and therapeutic possibilities. Pharmacopsychiatry 21: 285–287

    PubMed  Google Scholar 

  • Mueller TI, Keller MB, Leon AC, Solomon DA, Shea MT, Coryell W, Endicott J (1996) Recovery after 5 years of unremitting major depressive disorder. Arch Gen Psychiatry 53: 794–799

    PubMed  Google Scholar 

  • Mundo E, Walker M, Cate T, Macciardi F, Kennedy JL (2001) The role of serotonin transporter protein gene in antidepressant-induced mania in bipolar disorder: preliminary findings. Arch Gen Psychiatry 58: 539–544

    Article  PubMed  Google Scholar 

  • Murphy E (1983) The prognosis of depression in old age. Br J Psychiatry 142: 111–119

    PubMed  Google Scholar 

  • Nierenberg AA, Keefe BR, Leslie VC et al. (1999) Residual symptoms in depressed patients who respond acutely to fluoxetine. J Clin Psychiatry 60: 221–225

    PubMed  Google Scholar 

  • Paykel ES, Ramana R, Cooper Z, Hayhurst H, Kerr J, Barocka A (1995) Residual symptoms after partial remission: an important outcome in depression. Psychol Med 25: 1171–1180

    PubMed  Google Scholar 

  • Pollock BG, Ferrell RE, Mulsant BH et al. (2000) Allelic variation in the serotonin transporter promoter affects onset of paroxetine treatment response in late-life depression. Neuropsychopharmacology 23: 587–590

    PubMed  Google Scholar 

  • Praag HM (1977) New evidence for serotonin-deficient depression. Neuropsychobiology 3: 56–63

    PubMed  Google Scholar 

  • Praag HM, De Hann S (1980) Depression, vulnerability and 5-hydroxytryptophan prophylaxis. Psychiatry Res 3: 75–83

    Article  PubMed  Google Scholar 

  • Prien RF, Levine J (1984) Research and methodological issues for evaluating the therapeutic effectiveness of antidepressant drugs. Psychopharmacol Bull 20: 250–257

    PubMed  Google Scholar 

  • Reist C, Mazzanti C, Vu R, Tran D, Goldman D (2001) Serotonin transporter promoter polymorphism is associated with attenuated prolactin response to fenfluramine. Am J Med Genet 105: 363–368

    Article  PubMed  Google Scholar 

  • Robins E, Guze SB (1972) Invited address on classification. Classification of affective disorders: the primary-secondary, the endogenous-reactive, and the neurotic-psychotic concepts. In: Williams TA, Katz MM, Shield JA (eds) Recent advances in the psychobiology of the depressive illness. Government Printing Office, Washington, pp 283–293

    Google Scholar 

  • Rosenbaum AH, Schatzberg AF, Maruta T et al. (1980) MHPG as a predictor of antidepressant response to imipramine and maprotiline. Am J Psychiatry 137: 1090–1092

    PubMed  Google Scholar 

  • Rush AJ, Koran LM, Keller MB et al. (1998) The treatment of chronic depression, part 1: study design and rationale for evaluating the comparative efficacy of sertraline and imipramine as acute, crossover, continuation, and maintenance phase therapies. J Clin Psychiatry 59: 589–597

    PubMed  Google Scholar 

  • Schatzberg AF, Rosenbaum AH, Orsulak PJ et al. (1981) Toward a biochemical classification of depressive disorders. III: Pretreatment urinary MHPG levels as predictors of response to treatment with maprotiline. Psychopharmacology Berl 75: 34–38

    PubMed  Google Scholar 

  • Scott J (1988) Chronic depression. Br J Psychiatry 153: 287–297

    Google Scholar 

  • Serretti A, Lilli R, Mandelli L, Lorenzi C, Smeraldi E (2001) Serotonin transporter gene associated with lithium prophylaxis in mood disorders. Pharmacogenomics J 1: 71–77

    PubMed  Google Scholar 

  • Serretti A, Zanardi R, Rossini D, Cusin C, Lilli R, Smeraldi E (2001) Influence of tryptophan hydroxylase and serotonin transporter genes on fluvoxamine antidepressant activity. Mol Psychiatry 6: 586–592

    Article  PubMed  Google Scholar 

  • Sharan P, Saxena S (1998) Treatment-resistant depression: clinical significance, concept and management. Natl Med J India 11: 69–79

    PubMed  Google Scholar 

  • Sharma V, Mazmanian D, Persad E, Kueneman K (1995) A comparison of comorbid patterns in treatment-resistant unipolar and bipolar depression. Can J Psychiatry 40: 270–274

    PubMed  Google Scholar 

  • Sitaram N, Mendelson WB, Wyatt RJ, Gillin JC (1977) The time-dependent induction of REM sleep and arousal by physostigmine infusion during normal human sleep. Brain Res 122: 562–567

    Article  PubMed  Google Scholar 

  • Smeraldi E, Zanardi R, Benedetti F, Di Bella D, Perez J, Catalano M (1998) Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine. Mol Psychiatry 3: 508–511

    Article  PubMed  Google Scholar 

  • Solomon DA, Keller MB, Leon AC et al. (1997) Recovery from major depression. A 10-year prospective follow-up across multiple episodes. Arch Gen Psychiatry 54: 1001–1006

    PubMed  Google Scholar 

  • Steimer W, Muller B, Leucht S, Kissling W (2001) Pharmacogenetics: a new diagnostic tool in the management of antidepressive drug therapy. Clin Chim Acta 308: 33–41

    Article  PubMed  Google Scholar 

  • Sulser R, Mobley PL (1980) Biochemical effects of antidepressants on animals. In: Hoffmeister F, Stille G (eds) Handbook of experimental pharmacology: Psychiatric agents, part I. Springer, Berlin Heidelberg New York Tokio, pp 273–325

    Google Scholar 

  • Svendsen K, Christensen PG (1981) Duration of REM sleep latency as predictor of effect of antidepressant therapy. A preliminary report. Acta Psychiatr Scand 64: 238–243

    PubMed  Google Scholar 

  • Thase ME, Rush AJ, Howland RH et al. (2002) Double-blind switch study of imipramine or sertraline treatment of antidepressant-resistant chronic depression. Arch Gen Psychiatry 59: 233–239

    Article  PubMed  Google Scholar 

  • US Dept Health Human Services (1993) Clinical Practice Guideline Number 5: Depression in primary care, vol 2. Treatment of major depression. Rockville/MD, AHCPR publication 93-0551

    Google Scholar 

  • Wager SG, Klein DF (1988) Drug therapy strategies for treatment-resistant depression. Psychopharmacol Bull 24: 69–74

    PubMed  Google Scholar 

  • Weissman MM, Kasl SV, Klerman GL (1976) Follow-up of depressed women after maintenance treatment. Am J Psychiatry 133: 757–760

    PubMed  Google Scholar 

  • Whale R, Quested DJ, Laver D, Harrison PJ, Cowen PJ (2000) Serotonin transporter (5-HTT) promoter genotype may influence the prolactin response to clomipramine. Psychopharmacology (Berl) 150: 120–122

    Article  PubMed  Google Scholar 

  • Woggon B (1980) Veränderungen der psychopathologischen Symptomatik während 20tägiger antidepressiver oder neuroleptischer Behandlung. Psychiatr Clin Basel 13: 150–164

    PubMed  Google Scholar 

  • Woggon B (1983) Prognose der Pharmakotherapie. Enke, Stuttgart

    Google Scholar 

  • Wu WH, Huo SJ, Cheng CY, Hong CJ, Tsai SJ (2001) Association study of the 5-HT(6) receptor polymorphism (C267T) and symptomatology and antidepressant response in major depressive disorders. Neuropsychobiology 44: 172–175

    Google Scholar 

  • Yoshida K, Naito S, Takahashi H et al. (2002) Monoamine oxidase: A gene polymorphism, tryptophan hydroxylase gene polymorphism and antidepressant response to fluvoxamine in Japanese patients with major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry 26: 1279–1283

    Article  PubMed  Google Scholar 

  • Yu YW, Tsai SJ, Chen TJ, Lin CH, Hong CJ (2002) Association study of the serotonin transporter promoter polymorphism and symptomatology and antidepressant response in major depressive disorders. Mol Psychiatry 7: 1115–1119

    Article  PubMed  Google Scholar 

  • Zanardi R, Benedetti F, Di Bella D, Catalano M, Smeraldi E (2000) Efficacy of paroxetine in depression is influenced by a functional polymorphism within the promoter of the serotonin transporter gene. J Clin Psychopharmacol 20: 105–107

    Article  PubMed  Google Scholar 

  • Zanardi R, Serretti A, Rossini D et al. (2001) Factors affecting fluvoxamine antidepressant activity: influence of pindolol and 5-HTTLPR in delusional and nondelusional depression. Biol Psychiatry 50: 323–330

    Article  PubMed  Google Scholar 

Download references

Authors
  1. H.-J. Möller
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Klinik für Psychatrie und Psychotherapie, Charité — Universitätsklinik Berlin, Campus Charité Mitte (CCM), Schumannstr. 20/21, 10117, Berlin

    Michael Bauer  & Mazda Adli  & 

  2. Institut für Sozialmedizin, Epidemiologie und Gesundheitsökonomie, Charité — Universitätsklinik Berlin, Campus Charité Mitte (CCM), Luisenstr. 57, 10117, Berlin

    Anne Berghöfer

Rights and permissions

Reprints and permissions

Copyright information

© 2005 Springer Medizin Verlag Heidelberg

About this chapter

Cite this chapter

Möller, HJ. (2005). Therapieresistenz unipolarer depressiver Erkrankungen: Häufigkeit, Prädiktoren, Risikofaktoren. In: Bauer, M., Berghöfer, A., Adli, M. (eds) Akute und therapieresistente Depressionen. Springer, Berlin, Heidelberg. https://doi.org/10.1007/3-540-28049-9_2

Download citation

  • DOI: https://doi.org/10.1007/3-540-28049-9_2

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-40617-4

  • Online ISBN: 978-3-540-28049-1

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation